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Abstract 
Breast cancer (BC) is diagnosed in ≥ 65 year old women in about half of cases. Experts currently recommend that systemic therapy is 
offered to elderly patients with BC, if, based on their overall conditions and life expectancy, it can be reasonably anticipated that the benefits 
will outweigh the risks of treatment. Like for young subjects, the monoclonal antibody against human epidermal growth factor receptor-2 
(HER-2), trastuzumab, represents a valid therapeutic option when BC over-expresses this receptor. Unfortunately, administration of trastu-
zumab is associated with the occurrence of left ventricular dysfunction and chronic heart failure (CHF), possibly because of interference with 
the homeostatic functions of HER-2 in the heart. Registry-based, retrospective analyses have reported an incidence of CHF around 25% in 
elderly women receiving trastuzumab compared with 10%–15% in those not given any therapy for BC, and the risk of CHF has been 
estimated to be two-fold higher in > 60–65 year old trastuzumab users vs. non-users. Extremely advanced age and preexisting cardiac disease 
have been shown to predispose to trastuzumab cardiotoxicity. Therefore, selection of older patients for treatment with trastuzumab should be 
primarily based on their general status and the presence of comorbidities; previous chemotherapy, especially with anthracyclines, should be 
also taken into account. Once therapy has started, efforts should be made to ensure regular cardiac surveillance. The role of selected 
biomarkers, such as cardiac troponin, or new imaging techniques (three-dimension, tissue Doppler echocardiography, magnetic resonance 
imaging) is promising, but must be further investigated especially in the elderly. Moreover, additional studies are needed in order to better 
understand the mechanisms by which trastuzumab affects the old heart. 
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1  Introduction 
Dramatic improvements in socioeconomic conditions 
and health care resources have led to a substantial increase 
in life expectancy in industrialized countries, which are 
nowadays largely composed by elderly people. This demo-
graphical change has also impacted the medical field, and 
old patients have become common in any setting, including 
cardiology and oncology. This is especially the case with 
breast cancer (BC): according to the latest statistics, around 
half of BC are diagnosed in women aged 65 years or 
more.[1] 
BC of the elderly most often displays favorable biologi-
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cal characteristics, i.e., luminal molecular subtype, presence 
of hormone receptors (HR), low mitotic rate and nuclear 
grade, absence of p53 mutations, and no overexpression of 
epidermal growth factor receptor (EGFR) and human epi-
dermal growth factor receptor-2 (HER-2).[2–5] However, 
these features have not historically translated into better 
outcomes in older vs. younger patients: in fact, mortality is 
higher in the former than in the latter ones.[6] Various rea-
sons have been proposed to explain this paradox, such as 
competing risks of death from other diseases or the possibil-
ity that tumors exhibiting the same markers, but arising at 
young vs. old age, behave differently.[4,5] It has also been 
argued that adherence to treatment guidelines is poor and, 
particularly, that systemic chemotherapy is frequently not 
delivered in advanced age because of the concern of toxic-
ity.[7] The fact that elderly subjects have been underrepre-
sented in clinical trials and, thereby, few evidence-based 
data exist has probably strengthened the tendency to omit 
chemotherapy in this population.    
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Nevertheless, in the last years there has been a reapprai-
sal of the balance between benefits and side effects of che-
motherapy for old patients with BC. Retrospective analyses 
have shown that it may be effective and improve prognosis. 
This conclusion has also been reached by a limited number 
of dedicated trials of chemotherapy in the elderly and is 
expected to be confirmed by other ongoing clinical stud-
ies.[8–10] Hence, it is now recommended not to consider age 
as an exclusion criterion for cancer treatment as long as 
survival for a significant period of time is likely and the 
burden of comorbidity is low.[11] On the other hand, it holds 
true that toxicity of chemotherapy is enhanced at older 
ages.[8,9,12] 
As aforementioned, HER-2 positivity is relatively un-
common in BC of the elderly. Nonetheless, there is already 
quite a large experience with the use of the HER-2 targeting 
antibody, trastuzumab, in the geriatric population with 
HER-2 expressing tumors.[13,14] At present, trastuzumab may 
be indicated for old subjects with early stage BC—either 
HER-2 positive/HR negative or HER-2 positive/HR positive 
with lymph node invasion—or HER-2 positive metastatic 
BC.[11] The current opinion that adjuvant systemic therapy 
should be systematically considered for all eligible patients, 
regardless of age, is likely to foster the prescription of tras-
tuzumab in the elderly in the next future. Cardiotoxicity has 
been, and will remain, the main safety issue of this treat-
ment.[15] 
2  Search strategy 
PubMed and Embase were searched for articles written 
in English and including the following words in the title 
and/or abstract: trastuzumab, HER-2, ErbB-2, breast cancer, 
elderly, old.  
3  Mode of action of trastuzumab and patho-
genesis of its cardiotoxicity  
HER-2 (ErbB2 in rodents) is a membrane tyrosine kinase 
receptor belonging to the EGFR family, which also com-
prises HER-1 (also known as EGFR), HER-3, and HER-4 
(ErbB1, ErbB3, and ErbB4 in rodents). No ligand is known 
for HER-2. In normal tissues, ligand-stimulated EGFR, 
HER-3,and HER-4 form homodimers (a pair of the same 
receptors, e.g., EGFR/EGFR) or combine with HER-2 in 
heterodimers, and elicit a number of physiological cellular 
responses. In 20%–30% of BC, HER-2 is overexpressed 
and instead capable of undergoing ligand-independent 
homodimerization and intracellular signal transduction; 
moreover, the formation of heterodimers with HER-1 and  
HER-3 is facilitated. This leads to the activation of signaling 
pathways promoting proliferation and survival of tumor 
cells (Figure 1). As a consequence, BC with amplified 
HER-2 carries a dismal prognosis.[16,17] On the other hand, 
the existence of a subset of BC with high membrane levels 
of HER-2 has allowed the development of HER-2 directed 
therapies.[18] Trastuzumab was the first drug in this class.[19] 
It is a humanized monoclonal antibody against HER-2 that 
binds to subdomain IV of the extracellular domain of the 
receptor, halting the growth and causing the death of cancer 
cells likely through a number of mechanisms, such as induc-
tion of antibody-dependent immune cell-mediated cytotoxi-
city,[20] disruption of ligand-independent HER-2/HER-3 
interaction and downstream signaling,[21] and enhanced ac-
tivity of cell cycle inhibitor, p27.[22] Another FDA approved 
anti-HER-2 humanized monoclonal antibody is pertuzumab, 
which also targets the extracellular portion of HER-2, but at 
a different epitope in subdomain II.[23] Like trastuzumab, 
pertuzumab triggers antibody-dependent cellular cytotoxi-
city; in addition—and differently than trastuzumab—it pre-
vents ligand-initiated heterodimerization of HER-2 and 
other HER family members, especially HER-3.[24] Since 
trastuzumab and pertuzumab recognize different sites of 
HER-2 and act in a complementary way, their combination 
results in greater antitumor efficacy.[25] 
Small-molecule tyrosine kinase inhibitors constitute a 
second group of anti-HER-2 agents. The prototype, which 
has already entered clinical practice, is lapatinib, a dual 
blocker of both constitutive and ligand-induced EGFR and 
HER-2 phosphorylation and signaling.[26] Notably, lapatinib 
retains effectiveness in BC that has become resistant to 
trastuzumab.[27] Other HER tyrosine kinase inhibitors have 
been evaluated in early-phase clinical studies and are now in 
phase III trials.[28] 
As soon as trastuzumab was tested in patients, left ven-
tricular (LV) dysfunction turned out to be the main side 
effect of this drug and the leading cause of its discon-
tinuation.[29] Cardiotoxicity secondary to exposure to tras-
tuzumab is dose-independent and, thus, relatively 
unpredictable, and may culminate in overt congestive heart 
failure (CHF). On the other hand, it is reversible most of the 
time.[15,29] It has been reported that, after resolution of 
cardiac complications that have arisen following a first 
administration of trastuzumab, rechallenge with the drug 
may be safely attempted while maintaining standard 
medications for CHF.[30] Chemotherapy with anthracyclines, 
which also have long been known to be cardiotoxic, 
predisposes to trastuzumab cardiac side effects, whose 
incidence is highest when anthracyclines and trastuzumab  
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Figure 1.  Schematic representation of the NRG-1/HER-2 paradigm for trastuzumab cardiotoxicity. In oncology, trastuzumab is used 
to treat breast cancer in which HER-2 is overexpressed and spontaneously homodimerizes or forms heterodimers with other HER receptors, 
especially HER-3. As this ligand-independent activation of HER-2 sustains tumor growth and survival, trastuzumab halts the proliferation 
and causes the death of tumor cells (left side). In the heart, HER-2 functions as a dimerization partner of HER-4 after this latter is recruited 
by NRG-1 and regulates homeostatic cell responses. Off-target inhibition of cardiac HER-2 results in the disruption of part of NRG-1 de-
pendent signaling and, eventually, in alterations of structure and function that may be lethal to cardiomyocytes (right side). HER: human 
epidermal growth factor receptor; NRG-1: neuregulin. 
are given at the same time and decreases as the interval 
between anthracycline and trastuzumab infusion extends.[31] 
Surprisingly, the addition of pertuzumab to trastuzumab 
does not seem to raise the risk of LV dysfunction and 
CHF.[32,33] As far as lapatinib is concerned, the data collected 
so far about its cardiac safety are quite reassuring.[34] 
The exact mechanism of trastuzumab cardiotoxicity is 
yet to be pinpointed. Nonetheless, blockade of the action of 
neuregulin-1 (NRG-1), the ligand of ErbB4/HER-4, within 
the heart is believed to play a major role.[35] Studies based 
on animal models and primary cell cultures have revealed 
that NRG-1-induced ErbB4/ErbB4 homodimers and ErbB4/ 
ErbB2 heterodimers mediate protective responses of card-
iomyocytes to stress, including the one provoked by an-
thracyclines.[36] It is therefore assumed that trastuzumab and 
other ErbB2 antagonists make the myocardium more vu-
lnerable to the damage caused by anthracyclines—and, in 
principle, by other noxious factors—as they impede the 
formation of NRG-1-triggered ErbB4/ErbB2 heterodimers 
(Figure 1). Indeed, cardiomyocytes of transgenic mice in 
which ErbB2 expression is deleted specifically in the heart 
are more susceptible to anthracycline toxicity than wild-type 
cells,[37] and treatment of rat ventricular myocytes with an 
antibody against ErbB2 significantly worsens myofibrillar 
disarray due to incubation with anthracycline.[38] This is 
likely to happen also in humans, but it still has to be con-
firmed. In fact, the few data available about the expression 
of HER-2 in human hearts after anthracycline chemotherapy 
are discordant.[39,40] Interestingly, a downregulation of HER-2 
has been observed in the cardiac tissue of mice given 
trastuzumab, but not in cancer cells.[41–43] 
Some authors have pointed out that there is a discrepancy 
between the predicted pharmacodynamics of anti-HER-2 
agents and the reported rates of cardiotoxicity.[44] Trastu-
zumab should theoretically inhibit only the constitutive 
activity of tumor HER-2 and not affect HER-2 in the heart,  
where HER-2 is assumed to function exclusively as a di-
merization partner of ligand-occupied HER-4; clearly, this 
is not true. By contrast, off-target effects on the heart are 
anticipated for lapatinib, as it inhibits both ligand-indepen-
dent and ligand-dependent signaling of HER-2, but they 
seem to be actually less frequent than with trastuzumab. 
This inconsistency might be due to differences in recruit-
ment criteria between trastuzumab and lapatinib clinical 
trials, as well as to incomplete blockade of HER-2 and/or 
activation of rescue pathways by lapatinib.[44] Nevertheless, 
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it sheds doubts on the validity of the NRG-1/HER-2 para-
digm to explain the cardiotoxicity of HER-2 antagonists.  
Trastuzumab cardiotoxicity is commonly viewed as 
transient, since it has no or only minor histological corre-
lates and most often resolves after treatment withdra-
wal.[15,29] However, there are patients in whom LV function 
does not recover. This may happen because trastuzumab 
causes the death of a substantial proportion of cardiomyo-
cytes, as suggested by the finding that plasma concen-
trations of troponin I above 0.08 ng/mL after anthracyclines 
and trastuzumab therapy are associated with an almost three 
fold higher risk of suffering from a sustained reduction in 
LV ejection fraction (EF).[45] Alternatively, impairment of 
cardiac progenitor cells may be the substrate for long-lasting 
trastuzumab cardiotoxicity. In the last decade, apoptosis and 
senescence—i.e., inhibition of proliferation—of the endo-
genous pool of cardiac progenitor cells have been described 
as pivotal in the pathogenesis of persisting anthracyc-
line-induced cardiomyopathy.[35,46] Cardiac progenitor cells 
ensure an intrinsic, although limited capability of the heart 
to regenerate following injury. Therefore, their depletion 
may render the myocardium prone to accumulate minor 
lesions until symptoms appear.[47] Interestingly, trastuzumab 
has recently been shown to hinder the cardiomyogenic and 
angiogenic capacities of cardiac explants enriched for pro-
genitor cells.[48]  
4  Features of trastuzumab cardiotoxicity in 
elderly patients  
4.1  Frequency 
In the pivotal trial evaluating standard chemotherapy 
with or without the addition of trastuzumab for metastatic 
BC, NYHA class III or IV cardiac dysfunction was recorded 
in 16% of patients receiving anthracycline, cyclophos-
phamide, and trastuzumab vs. 3% of those treated only with 
anthracycline and cyclophosphamide, and in 2% of women 
given paclitaxel and trastuzumab vs. 1% of those assigned to 
paclitaxel alone.[49] Remarkably, no cardiac safety criteria 
were applied during enrollment.  
In subsequent trastuzumab trials, the incidence of cardiac 
side effects was smaller, probably because study design and 
patient selection were different. For instance, the National 
Surgical Adjuvant Breast and Bowel Project trial (NSABP) 
B-31, comparing anthracycline and cyclophosphamide 
followed by paclitaxel with anthracycline and cyclophos-
phamide followed by trastuzumab and paclitaxel, recruited 
subjects with node-positive, HER-2-positive BC and normal 
post-chemotherapy LVEF on multiple-gated acquisition 
(MUGA) scan. Source documents were reviewed by a panel 
of cardiologists for: (1) NYHA III or IV CHF with either a 
drop in LVEF of more than 10% to < 55% or a decrease of 
> 5% to less than the lower limit of normality; (2) possible/ 
probable cardiac death. The cumulative incidence of cardiac 
events was 4.1% in the trastuzumab group vs. 0.8% in the 
control one at three years and 4% vs. 1.3% at 7 years.[49,51] In 
a joint analysis of the NSABP B-31 trial and of the North 
Central Cancer Treatment Group (NCCTG) N9831 trial, 
which also assessed the efficacy and safety of trastuzumab 
in addition to paclitaxel after anthracycline (doxorubicin) 
and cyclophosphamide, the rates of CHF in the trastuzumab 
or control arms were 3.8% vs. 1.3% and 2.3% vs. 0.9%, 
respectively.[52] 
In a meta-analysis of eight major randomized clinical 
trials of trastuzumab for early and locally advanced BC, in 
which symptomatic CHF incidence ranged from 0.8% to 
14.2% in trastuzumab-treated patients vs. 0.2%–4.1% in 
control women, the relative risk of CHF associated with use 
of trastuzumab was 5.11 (90% CI:3.00–8.72).[53] The rela-
tive risk of LVEF decline was 1.83 (90% CI: 1.36–2.47), 
although heterogeneity for this outcome was substantial.[53] 
Elderly women participated in these trastuzumab clinical 
trials only to a minor extent. Keeping the example of 
NSABP B-31, only 16% of about 1600 evaluable subjects 
were ≥ 60 year old.[50] Nevertheless, in these studies age was 
found to predispose to cardiotoxicity of trastuzumab.[51,54]  
Real-world data confirm this finding. In an Italian registry 
in which 32.6% of patients were aged 60 years or more, the 
cumulative risk of trastuzumab-related cardiotoxicity for 
those younger or older than 70 years was 1.3% vs. 6.4% 
after 1 year, 2% vs. 9.8% after 2 years, and 2.2% vs. 9.8% 
after 3 years, respectively.[14] In another US registry in-
cluding cases of trastuzumab-treated HER-2 positive meta-
static BC, the incidence of grade ≥ 3 LV dysfunction was 
4.8%, 2.8%, and 1.5% for subjects ≥ 75, 65-74, or < 65 year 
old, respectively; and that of CHF 3.2%, 1.9%, and 1.5%, 
respectively.[55] In a multicentric cohort of German women 
receiving adjuvant trastuzumab the frequency of a drop in 
LVEF or CHF was 3.7% in the subgroup with < 65 years, 
3.9% in the one between 65 and 69 years, and 5.7% in the 
one with ≥ 70 years.[56] 
Table 1 summarizes the results of a series of retros-
pective analyses carried out to determine the frequency of 
trastuzumab cardiotoxicity specifically in cohorts of old 
women with BC. Overall, these investigations have shown 
that trastuzumab with or without anthracyclines confers a 
risk of suffering from CHF that can be roughly quantified as 
two times the one faced by trastuzumab non-users.[57–61] The 
most robust data come from Medicare records, with hazard 
ratios of HF from 1.95 (95% CI: 1.75–2.17) to 2.37 (95%  
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Table 1.  Studies of the incidence of trastuzumab cardiac side effects in elderly patients with breast cancer. 
Ref. 
No. 
Study population Treatment subgroups CHF 
Asymptomatic LVEF 
drop 
TZ: 414 (0.9%) 24.2%* 
A/TZ: 460 (1%) 15.5% 
A: 5979 (13%) 9.1% 
Non-A: 4922 (10.7%) 10% 
55 
Medicare 1998–2005 
45,997 women; ≥ 65 yrs 
Stage II-IV BC 
No previous CVD 
No therapy: 34,222 (74.4%) 9.6% 
NA 
TZ: 2203 (23.1%) 29.4% 
56 
Medicare 2005–2009 
9535 women; ≥ 66 yrs 
stage I-III BC 
No previous CHF 
No TZ: 7332 (76.9%) 18.9% 
NA 
TZ: 431 (1%) 26.7%# 
A/TZ: 431 (1%) 28.2% 
A: 5257 (11.5%) 15.3% 
Non-A: 2712 (5.9%) 17% 
57 
Medicare 2000–2007 
45,537 women; ≥ 67 yrs 
Stage I-III BC 
No therapy: 36,700 (80.6%) 16.9% 
NA 
58 
Single center 
45 women; ≥ 70 yrs 
Stage I-IV BC 
NS 8.9% 17.8% 
59 
Single center 2005–2010 
59 women; ≥ 70 yrs 
Stage I-IV BC 
No previous cardiac disease and basal 
LVEF ≥ 50% 
NS 1.9% 10.7% 
Data are presented as n (%). *5-year cumulative incidence; #3-year cumulative incidence. A: anthracycline; A/TZ: anthracycline and trastuzumab; BC: breast 
cancer; CHF: chronic heart failure; CVD: cardiovascular disease; LVEF: left ventricular ejection fraction: NA: not assessed; Non-A: non-anthracycline che-
motherapy; NS: not specified; TZ: trastuzumab. 
 
CI: 1.76–3.19).[57,58] The limitations of the retrospective 
approach and the data source used, which do not allow a 
strict control of confounding factors, must be acknowledged. 
On the other hand, these community practice-based 
observational studies take into account a sizable subset of 
patients who would have not been eligible for clinical trials 
of trastuzumab, but are actually treated in real-life. 
4.2  Risk factors and management  
In the Medicare population, the incidence of trastu-
zumab-related CHF in old women increased across age 
categories—i.e., it occured more often in ≥ 80 than > 65 
year old women.[58] Additional variables associated with 
trastuzumab cardiotoxicity in elderly subjects are black race, 
presence of cardiac comorbidities, such as coronary artery 
disease, and hypertension.[58] These factors likely operate by 
independently affecting the heart and making it susceptible 
to the toxicity of trastuzumab. Recent work, however, has 
revealed that inappropriate prescription of trastuzumab to 
frail subjects or without demonstration of HER-2 overex-
pression also enhances the risk of side effects. A signi-
ficantly higher rate of cardiac events has been reported in 
elderly patients who do not complete trastuzumab treatment 
because of very advanced age and/or too many comor-
bidities.[62] Based on billing codes in Medicare claims be-
tween 2000 and 2010, close to 5% of ≥ 65 years old women 
given trastuzumab did not receive prior HER-2 testing; they 
had similar survival to those who received chemotherapy 
and no trastuzumab, but experienced more often CHF.[63] 
There is general consensus that cardiac function should 
be monitored during trastuzumab treatment and that a 
reduction of LVEF of at least 10% to < 55% is clinically 
relevant, even if asymptomatic.[64] LVEF has mainly been 
evaluated by conventional two-dimensional (2D) trans-
thoracic echocardiography or radionuclide ventriculography 
(MUGA scans), which however may miss subtle abnor-
malities that might allow immediate recognition of trastu-
zumab cardiotoxicity and institution of a cardioprotective 
therapy, before cardiac function further declines or symp-
toms appear. Furthermore, the reliability of LVEF measure-
ment by 2D echocardiography has been questioned. An 
elegant work by Thavendiranathan and colleagues has 
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shown that the intrinsic variability of 2D EF values over 
time, secondary to physiological and technical aspects, may 
be > 0.10, which ironically corresponds to the > 0.10 cutoff 
defining asymptomatic cardiotoxicity.[65] 
Hence, a number of alternative strategies, relying on 
circulating biomarkers and/or imaging techniques, have 
been suggested for early and accurate detection of trastu-
zumab toxicity.[15]  
Cardiac troponin may be a good marker of trastuzumab 
cardiac side effects,[45,66] although this conclusion has not 
been reached by all authors.[67] In a multi-center cohort of 
BC patients undergoing treatment with doxorubicin and 
trastuzumab, it has been found that myeloperoxidase also 
predicts cardiotoxicity of these drugs and that the combina-
tion of troponin I and myeloperoxidase may offer additive 
information.[68] This same study and another one have shown 
no correlation between levels of high-sensitivity C-reactive 
protein (CRP) and LVEF decline, in contrast with a third 
smaller investigation in which, instead, high-sensitivity CRP 
proved to be a valuable marker of trastuzumab-induced car-
diotoxicity.[69,70] B-type natriuretic peptide (BNP) or N-ter-
minal proBNP seem to have no utility either.[66,67]  
Among imaging tools, newer echocardiography methods 
and cardiac magnetic resonance hold promise for improving 
the diagnosis of LV remodeling and dysfunction due to 
trastuzumab. Three-dimensional echocardiography has been 
suggested to perform better than 2D echocardiography in 
measuring LVEF and volumes and to be more reproducible 
over time and between different examiners.[65,71] In addition, 
LV strain and tissue Doppler parameters may allow early 
identification of trastuzumab cardiotoxicity, before LVEF 
changes.[67,72] The same goal may be achieved with cardiac 
magnetic resonance,[73] which may also reveal a peculiar 
linear pattern of late gadolinium enhancement in the 
subepicardial region of the LV lateral wall.[67,74] 
However, it must be taken into consideration that the 
studies addressing the role of the latest echocardiography 
techniques and cardiac magnetic resonance in trastuzumab 
cardiomyopathy are still few and small-sized; moreover, the 
performance and feasibility of these imaging modalities in 
old and especially very old BC patients have not yet been 
explored, as well as their cost-effectiveness. In addition, an 
approach that integrates the use of biomarkers and imaging 
results to detect chemotherapy cardiotoxicity has been 
presented,[75] but no data exist as far as trastuzumab is con-
cerned.      
Unfortunately, even cardiologic consultation and cardiac 
monitoring of trastuzumab therapy with standard echocar-
diography or ventriculography are often disregarded in the 
elderly. Among over 2,000 Medicare > 65 year old patients, 
who received adjuvant trastuzumab for stage I-III invasive 
BC between 2005 and 2009 and did not have history of 
CHF, baseline cardiac evaluation was performed in 78.8% 
and subsequent follow-up only in 42.6% (32% of the entire 
cohort).[76] Interestingly, after adjustment for multiple con-
founders, a positive association was found between being 
monitored for cardiac safety over time and being diagnosed 
in more recent years or being referred to a physician of 
female gender or graduated after 1990, highlighting that 
awareness of trastuzumab cardiotoxicity, or anyway atten-
tion to it, is not the same in the entire medical community.   
Besides trastuzumab discontinuation, initiation of beta- 
blocker and ACE inhibitor is recommended if cardiotoxicity 
develops.[15,29,35] Even though these drugs may favorably 
influence the cardiac HER system,[77] their use is at present 
empirical and prompted by the knowledge of their positive 
effects on cardiac remodeling and on the maladaptive 
neurohormonal responses occurring in CHF of any etiology. 
The ongoing Multidisciplinary Approach to Novel Thera-
pies in Cardiology Oncology Research Trial (MANTICORE 
101—Breast) is evaluating the effectiveness of perindopril 
or bisoprolol in primary prevention of trastuzumab-induced 
modifications in LV geometry.[78] Since the LV will be 
evaluated by magnetic resonance imaging, important 
information about the role of this latter in the cardiologic 
follow-up after trastuzumab therapy will be also obtained.  
5  Conclusions 
Trastuzumab therapy carries a significant risk of cardio-
toxicity in the elderly like at a younger age, with an in-
cidence of CHF in trastuzumab recipients that may be twice 
as high as it is in women not given trastuzumab.  
Careful selection of patients is mandatory to avoid un-
necessary prescription of trastuzumab and, therefore, un-
justified risk of cardiac side effects. Treatment should be 
offered only to subjects who can be reasonably assumed to 
be able to complete it, keeping in mind that extremely 
advanced age and preexisting cardiac disease predispose to 
trastuzumab cardiotoxicity. Efforts should be then made to 
ensure regular cardiac surveillance.  
Future studies are needed to determine whether selected 
biomarkers or new imaging techniques may be employed in 
the geriatric population for timely detection and treatment of 
trastuzumab cardiac side effects. At the preclinical level, a 
better understanding of the mechanisms by which trastu-
zumab specifically affects the old heart is warranted. 
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